Cited by 112Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesCriminal Justice and Corrections Analysis

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.

A randomized controlled trial of prison-initiated buprenorphine: Prison outcomes and community treatment entry

Open access

Gordon, Michael S., Kinlock, Timothy W., Schwartz, Robert P., Fitzgerald, Terrence T., O’Grady, Kevin E., Vocci, Frank J.·2014·Drug and Alcohol Dependence

DOI 10.1016/j.drugalcdep.2014.05.011PMC PMC4129444

Open this paper in CoChat — free account

Abstract

Background Buprenorphine is a promising treatment for heroin addiction. However, little is known regarding its provision to pre-release prisoners with heroin dependence histories who were not opioid-tolerant, the relative effectiveness of the post-release setting in which it is provided, and gender differences in treatment outcome in this population.Methods This is the first randomized clinical trial of prison-initiated buprenorphine provided to male and female inmates in the US who were previously heroin-dependent prior to incarceration. A total of 211 participants with 3-9 months remaining in prison were randomized to one of four conditions formed by crossing In-Prison Treatment Condition (received buprenorphine vs. counseling only) and Post-release Service Setting (at an opioid treatment center vs. a community health center). Outcome measures were: entered prison treatment; completed prison treatment; and entered community treatment 10 days post-release.Results There was a significant main effect (p=.006) for entering prison treatment favoring the In-Prison buprenorphine Treatment Condition (99.0% vs. 80.4%). Regarding completing prison treatment, the only significant effect was Gender, with women significantly (p<.001) more likely to complete than men (85.7% vs. 52.7%). There was a significant main effect (p=.012) for community treatment entry, favoring the In-Prison buprenorphine Treatment Condition (47.5% vs. 33.7%).Conclusions Buprenorphine appears feasible and acceptable to prisoners who were not opioid-tolerant and can facilitate community treatment entry. However, concerns remain with in-prison treatment termination due to attempted diversion of medication.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.drugalcdep.2014.05.011

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Applied logistic regression
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
Categorical Data Analysis
Hapeman, D. E., & Agresti, A. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,407
The Fifth Edition of the Addiction Severity Index.
Mclellan, A., Kushner, H., Metzger, D., Peters, R., Smith, I. E., Grissom, G. R., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,280
A solution to the problem of separation in logistic regression
Heinze, G., & Schemper, M. (2002) · Statistics in Medicine · doi:10.1002/sim.1047 · Cited by 2,711
Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002209.pub2 · Cited by 1,654
Substance abuse and dependence in prisoners: a systematic review
Fazel, S., Bains, P., & Doll, H. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01316.x · Cited by 839
Meta‐analysis of drug‐related deaths soon after release from prison
Merrall, E. L. C., Kariminia, A., Binswanger, I. A., HOBBS, M. S. T., Farrell, M., Marsden, J., Hutchinson, S. J., & Bird, S. M. (2010) · Addiction · doi:10.1111/j.1360-0443.2010.02990.x · Cited by 689
Categorical Data Analysis.
Lendrem, D. W., & Agresti, A. (1991) · Journal of the Royal Statistical Society Series D (The Statistician) · doi:10.2307/2348741 · Cited by 616
Substance Abuse in Women
Greenfield, S. F., Back, S. E., Lawson, K., & Brady, K. T. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2010.01.004 · Cited by 602
Treating Drug Abuse and Addiction in the Criminal Justice System: Improving Public Health and Safety
Chandler, R. K., Fletcher, B. W., & Volkow, N. D. (2009) · JAMA · doi:10.1001/jama.2008.976 · Cited by 583

Show all 46 references

Sorted by citations

Mental health of prisoners: prevalence, adverse outcomes, and interventions
Fazel, S., Hayes, A. J., Bartellas, K., Clerici, M., & Trestman, R. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30142-0 · Cited by 992
Opioid use disorder
Strang, J., Volkow, N. D., Degenhardt, L., Hickman, M., Johnson, K., Koob, G. F., Marshall, B. D. L., Tyndall, M., & Walsh, S. L. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0137-5 · Cited by 639
Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis
Santo, T., Clark, B., Hickman, M., Grebely, J., Campbell, G., Sordo, L., Chen, A., Tran, L. T., Bharat, C., Padmanathan, P., et al. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.0976 · Cited by 607
Prevention and Treatment of Opioid Misuse and Addiction: A Review
Volkow, N. D., Jones, E. B., Einstein, E. B., & Wargo, E. M. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3126 · Cited by 596
Extended-release naltrexone to prevent opioid relapse in criminal justice offenders
Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V., Boney, T. Y., Hoskinson, R. A., Wilson, D., McDonald, R., Rotrosen, J., Gourevitch, M. N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505409 · Cited by 315
Self-citation
Effectiveness of medication assisted treatment for opioid use in prison and jail settings: A meta-analysis and systematic review
Moore, K. E., Roberts, W., Reid, H. H., Smith, K. M. Z., Oberleitner, L., & McKee, S. A. (2018) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2018.12.003 · Cited by 229
A conceptual model for understanding post-release opioid-related overdose risk
Joudrey, P. J., Khan, M. R., Wang, E. A., Scheidell, J. D., Edelman, E. J., McInnes, D. K., & Fox, A. D. (2019) · Addiction Science & Clinical Practice · doi:10.1186/s13722-019-0145-5 · Cited by 208
Prescription opioid abuse: Problems and responses
Compton, W. M., Boyle, M., & Wargo, E. M. (2015) · Preventive Medicine · doi:10.1016/j.ypmed.2015.04.003 · Cited by 186
Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review
Malta, M., Varatharajan, T., Russell, C., Pang, M., Bonato, S., & Fischer, B. (2019) · PLoS Medicine · doi:10.1371/journal.pmed.1003002 · Cited by 171
Underlying Factors in Drug Overdose Deaths
Dowell, D., Noonan, R. K., & Houry, D. (2017) · JAMA · doi:10.1001/jama.2017.15971 · Cited by 162
The relationship between incarceration history and overdose in North America: A scoping review of the evidence
Mital, S., Wolff, J., & Carroll, J. J. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108088 · Cited by 122
Beyond the walls: Risk factors for overdose mortality following release from the Philadelphia Department of Prisons
Pizzicato, L. N., Drake, R., Domer-Shank, R. B., Johnson, C. C., & Viner, K. M. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.04.034 · Cited by 118
Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder
Fox, A. D., Maradiaga, J., Weiss, L., Sanchez, J., Starrels, J. L., & Cunningham, C. O. (2015) · Addiction Science & Clinical Practice · doi:10.1186/s13722-014-0023-0 · Cited by 101
Predictors of early dropout in outpatient buprenorphine/naloxone treatment
Marcovitz, D. E., McHugh, R. K., Volpe, J., Votaw, V. R., & Connery, H. S. (2016) · American Journal on Addictions · doi:10.1111/ajad.12414 · Cited by 92
The impact of the opioid crisis on U.S. state prison systems
Scott, C. K., Dennis, M. L., Grella, C. E., Mischel, A. F., & Carnevale, J. T. (2021) · Health & Justice · doi:10.1186/s40352-021-00143-9 · Cited by 84
Epidemiology of the U.S. opioid crisis: the importance of the vector
Compton, W. M., & Jones, C. M. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14209 · Cited by 86
Association between jail‐based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011–17
Lim, S., Cherian, T., Katyal, M., Goldfeld, K. S., McDonald, R. D., Wiewel, E. W., Khan, M. R., Krawczyk, N., Braunstein, S., Murphy, S. M., et al. (2022) · Addiction · doi:10.1111/add.16071 · Cited by 76
Fatal and nonfatal opioid overdose risk following release from prison: A retrospective cohort study using linked administrative data
Hartung, D. M., McCracken, C. M., Nguyen, T. D., Kempany, K. G., & Waddell, E. N. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.208971 · Cited by 75
Interventions for incarcerated adults with opioid use disorder in the United States: A systematic review with a focus on social determinants of health
Sugarman, O. K., Bachhuber, M. A., Wennerstrom, A., Bruno, T., & Springgate, B. F. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227968 · Cited by 66
A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release
Gordon, M., Kinlock, T. W., Schwartz, R. P., O’Grady, K. E., Fitzgerald, T. T., & Vocci, F. J. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.11.037 · Cited by 65
Self-citation
Pharmacotherapy for opioid dependence in jails and prisons: research review update and future directions
Schwartz, R. P., Sharma, A., O’Grady, K. E., Kelly, S., Gryczynski, J., & Mitchell, S. G. (2016) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s81602 · Cited by 63
Self-citation
“I Kicked the Hard Way. I Got Incarcerated.” Withdrawal from Methadone During Incarceration and Subsequent Aversion to Medication Assisted Treatments
Maradiaga, J., Nahvi, S., Cunningham, C. O., Sanchez, J., & Fox, A. D. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2015.11.004 · Cited by 59
In their own voices: Breaking the vicious cycle of addiction, treatment and criminal justice among people who inject drugs in Ukraine
Mazhnaya, A., Bojko, M. J., Marcus, R., Filippovych, S., Islam, Z., Дворяк, С., & Altice, F. L. (2016) · Drugs Education Prevention and Policy · doi:10.3109/09687637.2015.1127327 · Cited by 54
Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings
Dunlop, A. J., White, B., Roberts, J., Cretikos, M. A., Attalla, D., Ling, R., Searles, A., Mackson, J. M., Doyle, M., McEntyre, E., et al. (2021) · Addiction · doi:10.1111/add.15627 · Cited by 52
A Phase 4, Pilot, Open-Label Study of VIVITROL® (Extended-Release Naltrexone XR-NTX) for Prisoners
Gordon, M., Kinlock, T. W., Vocci, F. J., Fitzgerald, T. T., Memisoglu, A., & Silverman, B. L. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2015.07.005 · Cited by 51
Self-citation
Cost‐effectiveness of extended release naltrexone to prevent relapse among criminal justice‐involved individuals with a history of opioid use disorder
Murphy, S. M., Polsky, D. E., Lee, J. D., Friedmann, P. D., Kinlock, T. W., Nunes, E. V., Bonnie, R. J., Gordon, M., Chen, D. T., Boney, T. Y., et al. (2017) · Addiction · doi:10.1111/add.13807 · Cited by 51
Self-citation
Attitudes Toward Addiction, Methadone Treatment, and Recovery Among HIV-Infected Ukrainian Prisoners Who Inject Drugs: Incarceration Effects and Exploration of Mediators
Polonsky, M., Rozanova, J., Azbel, L., Bachireddy, C., Izenberg, J. M., Kiriazova, T. K., Дворяк, С., & Altice, F. L. (2016) · AIDS and Behavior · doi:10.1007/s10461-016-1375-0 · Cited by 48
Medications for opioid use disorder during incarceration and post-release outcomes
Cates, L., & Brown, A. (2023) · Health & Justice · doi:10.1186/s40352-023-00209-w · Cited by 47
Opioid Use Disorder Stigma, Discrimination, and Policy Attitudes in a National Sample of U.S. Young Adults
Adams, Z. W., Taylor, B. G., Flanagan, E. A., Kwon, E., Johnson-Kwochka, A. V., Elkington, K. S., Becan, J. E., & Aalsma, M. C. (2021) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2020.12.142 · Cited by 46
A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia
Larney, S., ZADOR, D. A., Sindicich, N., & Dolan, K. A. (2016) · Drug and Alcohol Review · doi:10.1111/dar.12442 · Cited by 43
Massachusetts Justice Community Opioid Innovation Network (MassJCOIN)
Evans, E., Stopka, T. J., Pivovarova, E., Murphy, S. M., Taxman, F. S., Ferguson, W. J., Bernson, D., Santelices, C., McCollister, K. E., Hoskinson, R. A., et al. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108275 · Cited by 42
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community
Paola, A. D., Lincoln, T., Skiest, D. J., Desabrais, M., Altice, F. L., & Springer, S. A. (2014) · Contemporary Clinical Trials · doi:10.1016/j.cct.2014.09.002 · Cited by 36
Interventions for drug-using offenders with co-occurring mental health problems.
Perry, A., James, M. M.-S., Burns, L., Hewitt, C., Glanville, J. M., Aboaja, A., Thakkar, P., Kumar, K. M. S., Pearson, C., Wright, K., et al. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010901.pub3 · Cited by 5
Extended-release naltrexone for opioid use disorder started during or following incarceration
Lincoln, T., Johnson, B. D., McCarthy, P., & Alexander, E. (2017) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2017.04.002 · Cited by 32
Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: Rationale and design of a randomized controlled effectiveness trial
Lee, J. D., Friedmann, P. D., Boney, T. Y., Hoskinson, R. A., McDonald, R. D., Gordon, M., Fishman, M. J., Chen, D. T., Bonnie, R. J., Kinlock, T. W., et al. (2015) · Contemporary Clinical Trials · doi:10.1016/j.cct.2015.01.005 · Cited by 29
Self-citation
Interventions for female drug-using offenders
Perry, A., Neilson, M., James, M. M., Glanville, J., Woodhouse, R., & Hewitt, C. E. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010910.pub2 · Cited by 32
Evaluating the implementation of a prisoner re-entry initiative for individuals with opioid use and mental health disorders: Application of the consolidated framework for implementation research in a cross-system initiative
Hanna, J. E., Kubiak, S. P., Pasman, E., Gaba, A., Andre, M. A., Smelson, D. A., & Pinals, D. A. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.06.012 · Cited by 30
Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts
Chatterjee, A., Weitz, M., Savinkina, A. A., Macmadu, A., Madushani, R. W. M. A., Potee, R. A., Ryan, D., Murphy, S. M., Walley, A. Y., & Linas, B. P. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.7036 · Cited by 27
Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment
Gordon, M., Vocci, F. J., Fitzgerald, T. T., O’Grady, K. E., & O’Brien, C. P. (2016) · Contemporary Clinical Trials · doi:10.1016/j.cct.2016.12.015 · Cited by 23
Self-citation
Pre-exposure prophylaxis awareness and interest among participants in a medications for addiction treatment program in a unified jail and prison setting in Rhode Island
Peterson, M., Macmadu, A., Truong, A. Q., Rich, J. D., Pognon, K., Lurie, M. N., Clarke, J. G., & Brinkley‐Rubinstein, L. (2019) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2019.08.015 · Cited by 23
Medication-Assisted Treatment in Problem-solving Courts: A National Survey of State and Local Court Coordinators
Faragó, F., Blue, T. R., Smith, L. R., Witte, J. C., Gordon, M., & Taxman, F. S. (2022) · Journal of Drug Issues · doi:10.1177/00220426221109948 · Cited by 22
Self-citation
Buprenorphine Dose Induction in Non-Opioid-Tolerant Pre-release Prisoners
Vocci, F., Schwartz, R., Wilson, M. E., Gordon, M., Kinlock, T., Fitzgerald, T. T., O'Grady, K., & Jaffe, J. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.09.001 · Cited by 24
Self-citation
Use of non–prescribed buprenorphine in the criminal justice system: Perspectives of individuals recently released from incarceration
Gryczynski, J., Lee, J. D., Dušek, K., McDonald, R. D., Sharma, A., Malone, M., Monico, L. B., Cheng, A., DeVeaugh‐Geiss, A., & Chilcoat, H. D. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108349 · Cited by 22
Budget impact tool for the incorporation of medications for opioid use disorder into jail/prison facilities
Ryan, D. A., Montoya, I. D., Koutoujian, P. J., Siddiqi, K., Hayes, E., Jeng, P. J., Cadet, T., McCollister, K. E., & Murphy, S. M. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2022.208943 · Cited by 21
Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes
Bovell-Ammon, B. J., Yan, S., Dunn, D., Evans, E., Friedmann, P. D., Walley, A. Y., & Larochelle, M. R. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.2732 · Cited by 21
“We'll be able to take care of ourselves” – A qualitative study of client attitudes toward implementing buprenorphine treatment at syringe services programs
Frost, T., Deutsch, S., Brown, S., Lemien, E., Cunningham, C. O., & Fox, A. D. (2021) · Substance Abuse · doi:10.1080/08897077.2021.1901173 · Cited by 21
A meta-analysis on the effects of incarceration-based opioid substitution treatment
Boksán, K., Dechant, M., Weiss, M., Hellwig, A., & Stemmler, M. P. (2022) · Medicine Science and the Law · doi:10.1177/00258024221118971 · Cited by 20
Does incarceration influence patients’ goals for opioid use disorder treatment? A qualitative study of buprenorphine treatment in jail
Vail, W. L., Faro, E. Z., Watnick, D. L., Giftos, J., & Fox, A. D. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108529 · Cited by 22
Opioid-specific medication-assisted therapy and its impact on criminal justice and overdose outcomes
Strange, C. C., Manchak, S. M., Hyatt, J. M., Petrich, D. M., Desai, A., & Haberman, C. P. (2022) · Campbell Systematic Reviews · doi:10.1002/cl2.1215 · Cited by 19
Extended-Release Naltrexone for Alcohol and Opioid Problems in Missouri Parolees and Probationers
Crits-Christoph, P. F., Lundy, C., Stringer, M. G., Gallop, R., & Gastfriend, D. R. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2015.03.003 · Cited by 19
Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model
Ling, R., White, B., Roberts, J., Cretikos, M. A., Howard, M. V. A., Haber, P., Lintzeris, N., Reeves, P., Dunlop, A. J., & Searles, A. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08687-8 · Cited by 18
Evaluation of Treatment and Other Factors That Lead to Drug Court Success, Substance Use Reduction, and Mental Health Symptomatology Reduction Over Time
Baughman, M., Tossone, K., Singer, M. I., & Flannery, D. J. (2018) · International Journal of Offender Therapy and Comparative Criminology · doi:10.1177/0306624x18789832 · Cited by 18
Interventions for female drug-using offenders.
Perry, A., James, M. M.-S., Burns, L., Hewitt, C. E., Glanville, J. M., Aboaja, A., Thakkar, P., Kumar, K. M. S., Pearson, C., & Wright, K. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010910.pub3 · Cited by 7
Medications for Opioid Use Disorder Among Incarcerated Individuals: a Review of the Literature and Focus on Patient Preference
Puglisi, L. B., Bedell, P. S., Steiner, A., & Wang, E. A. (2019) · Current Addiction Reports · doi:10.1007/s40429-019-00283-x · Cited by 17
Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials
Murphy, S. M., Jeng, P. J., Poole, S. A., Jalali, A., Vocci, F. J., Gordon, M., WOODY, G. E., & Polsky, D. E. (2020) · Addiction Science & Clinical Practice · doi:10.1186/s13722-020-00188-5 · Cited by 19
Self-citation
A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail
Gordon, M., Mitchell, S. G., Blue, T. R., Vocci, F. J., Fishman, M. J., Murphy, S. M., Couvillion, K., Maher, K. M., Ryan, D., Wenzel, K. R., et al. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.108241 · Cited by 16
Self-citation
Medications for Opioid use Disorder in State Prisons: Perspectives of Formerly Incarcerated Persons
Treitler, P. C., Enich, M., Reeves, D., & Crystal, S. (2022) · Substance Abuse · doi:10.1080/08897077.2022.2060448 · Cited by 14
Reimbursing incarcerated individuals for participation in research: A scoping review
Mambro, A., Afshar, A., Leone, F., Dussault, C., Stoove, M. A., Savulescu, J., Rich, J. D., Rowan, D. H., Sheehan, J., & Kronfli, N. (2023) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2023.104283 · Cited by 16
Initiating buprenorphine treatment prior to versus after release from prison: Arrest outcomes
Gordon, M., Blue, T. R., Couvillion, K. A., Schwartz, R. P., O’Grady, K. E., Fitzgerald, T. T., & Vocci, F. J. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.04.010 · Cited by 14
Self-citation
Cost and cost-effectiveness of interim methadone treatment and patient navigation initiated in jail
Zarkin, G. A., Orme, S., Dunlap, L. J., Kelly, S. M., Mitchell, S. G., O’Grady, K. E., & Schwartz, R. P. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108292 · Cited by 13
Self-citation
Interim methadone and patient navigation in jail: Rationale and design of a randomized clinical trial
Schwartz, R. P., Kelly, S. M., Mitchell, S. G., Dunlap, L. J., Zarkin, G. A., Sharma, A., O’Grady, K. E., & Jaffe, J. H. (2016) · Contemporary Clinical Trials · doi:10.1016/j.cct.2016.06.002 · Cited by 13
Self-citation
Recent Incarceration and Buprenorphine Maintenance Treatment Outcomes among Human Immunodeficiency Virus–Positive Patients
Riggins, D. P., Cunningham, C. O., Ning, Y. M., & Fox, A. D. (2016) · Substance Abuse · doi:10.1080/08897077.2016.1220443 · Cited by 13
Routes of non-traditional entry into buprenorphine treatment programs
Champagne‐Langabeer, T., Swank, M. W., & Langabeer, J. R. (2020) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-020-0252-z · Cited by 13
Prisoners as Patients: The Opioid Epidemic, Medication-Assisted Treatment, and the Eighth Amendment
Linden, M., Marullo, S., Bone, C., Barry, D. T., & Bell, K. (2018) · The Journal of Law Medicine & Ethics · doi:10.1177/1073110518782926 · Cited by 11
Innovations in efforts to expand treatment for opioid use disorder
Sigmon, S. C. (2019) · Preventive Medicine · doi:10.1016/j.ypmed.2019.105818 · Cited by 11
Deaths in Custody and following Release
Fox, A. D., Moore, A., Binswanger, I. A., & Kinner, S. A. (2019) · Journal of Health and Human Services Administration · doi:10.1177/107937391904100403 · Cited by 10
“A lot of moving parts”: Recovery home challenges linking and housing individuals with criminal legal system involvement
Dewey, J. M., Bell, J. S., Konchak, J. N., Hinami, K., & Watson, D. P. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209473 · Cited by 9
Exploring mental health comorbidities and opioid agonist treatment coverage among people in prison: A national cohort study 2010–2019
Bukten, A., Skjærvø, I., & Stavseth, M. R. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.110896 · Cited by 9
Frequent Drug Use and Negative Employment Outcomes among the Criminally Active
Bellair, P. E., Vuolo, M., & LaPlant, E. G. (2017) · Substance Use & Misuse · doi:10.1080/10826084.2017.1388260 · Cited by 12
Impact of prerelease methadone on mortality among people with HIV and opioid use disorder after prison release: results from a randomized and participant choice open-label trial in Malaysia
Bazazi, A. R., Culbert, G. J., Wegman, M. P., Heimer, R., Kamarulzaman, A., & Altice, F. L. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07804-6 · Cited by 8
Access to medications for opioid use disorder for formerly incarcerated individuals during community reentry: a mini narrative review
Chladek, J. S., & Chui, M. A. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1377193 · Cited by 8
New Challenges and Opportunities for Opioid Agonist Treatment Access and Retention: A Scoping Review
Power, N., Archambault, L., & Perreault, M. (2024) · Journal of Drug Issues · doi:10.1177/00220426241269828 · Cited by 10
A randomized controlled trial of buprenorphine for probationers and parolees: Bridging the gap into treatment
Gordon, M., Vocci, F. J., Taxman, F. S., Fishman, M. J., Sharma, B., Blue, T. R., & O’Grady, K. E. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2019.02.009 · Cited by 8
Self-citation
Drugs and Addiction Science: NIDA Celebrates 50 Years of Research and Looks to the Future
Volkow, N. D. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230880 · Cited by 8
Unmet need for medication for opioid use disorder among persons who inject drugs in 23 U.S. cities
Handanagić, S., Broz, D., Finlayson, T., Kanny, D., & Wejnert, C. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.111251 · Cited by 7
Treating opioid use disorders in the criminal justice system with pharmacotherapy
Schenk, S., Eisenbarth, H., & Dixon, L. (2020) · Forensic Science International Mind and Law · doi:10.1016/j.fsiml.2020.100009 · Cited by 6
Recovery support specialists inside the jail: a program description of treatment engagement for opioid use disorder
Martin, M. P., Phillips, M. A., Saxon, M., Love, K., Cessna, L., Woodard, D. L., Page, M., Curry, K. H., Paone, A., Pennington-Stallcup, B., et al. (2021) · International Journal of Prisoner Health · doi:10.1108/ijph-12-2020-0102 · Cited by 6
Longitudinal analysis of HIV-risk behaviors of participants in a randomized trial of prison-initiated buprenorphine
Blue, T. R., Gordon, M., Schwartz, R. P., Couvillion, K. A., Vocci, F. J., Fitzgerald, T. T., & O’Grady, K. E. (2019) · Addiction Science & Clinical Practice · doi:10.1186/s13722-019-0172-2 · Cited by 6
Self-citation
Mortality, incarceration and cost implications of fentanyl felonization laws: A modeling study
Savinkina, A. A., Jurecka, C., Gonsalves, G., & Barocas, J. A. (2023) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2023.104175 · Cited by 5
Combatting the Opioid Crisis From Prison: Initiating Opioid Agonist Therapy
McIntyre, J. L. (2018) · Journal of Forensic Nursing · doi:10.1097/jfn.0000000000000221 · Cited by 5
Medications for Opioid Use Disorder Helpful or Placebo? An Evaluation of the Effectiveness of MOUD in Carceral Settings
Palmieri, M., & Clark, V. A. (2024) · American Journal of Criminal Justice · doi:10.1007/s12103-024-09784-6 · Cited by 4
Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation
Regenstreif, L., Sadik, M., Beaulieu, E., Bodkin, C., Kiefer, L., Guenter, D., Lee, P. W. P., & Kouyoumdjian, F. G. (2022) · Health & Justice · doi:10.1186/s40352-022-00174-w · Cited by 4
Women with opioid use disorders in the criminal justice system: A brief report
Ea, E., & Ma, S. (2015) · Cited by 4
Populations at Special Health Risk: Incarcerated
Macmadu, A., Reddy, M., Tomasulo, A., Coyle, A., & Rich, J. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803678-5.00342-8 · Cited by 4
Moving Beyond the Medication or Psychosocial Treatment Dichotomy to Address the Opioid Epidemic
Stimmel, M. A., Smelson, D. A., & Finlay, A. K. (2022) · Psychiatric Services · doi:10.1176/appi.ps.202100627 · Cited by 3
Kaum Geschlechtsunterschiede bei Opioidkonsumierenden in Haft
Boksán, K., Weiss, M., Geißelsöder, K., Dechant, M., Endres, J., Breuer, M. M., Stemmler, M., & Wodarz, N. (2023) · Forensische Psychiatrie Psychologie Kriminologie · doi:10.1007/s11757-022-00747-3 · Cited by 3
Treatment initiations and opioid overdoses among recently incarcerated people after adoption of the take-home methadone policy
Barsky, B. A., Yan, S., & Rosenthal, M. B. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112775 · Cited by 2
Barriers and facilitators to community pharmacist-provided injectable naltrexone for formerly incarcerated individuals during community reentry
Chladek, J. S., & Chui, M. A. (2025) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2025.100561 · Cited by 2
Psychopharmacology in the Jail Setting
Kushner, D. B., Stossel, L. M., & Khan, M. A. “. (2023) · Oxford University Press eBooks · doi:10.1093/oso/9780197524794.003.0008 · Cited by 1
Extended-release buprenorphine induction in opioid non-tolerant incarcerated individuals
Gordon, M., Blue, T. R., Vocci, F. J., Mitchell, S. G., Wenzel, K. R., & Fishman, M. J. (2024) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2024.100261 · Cited by 1
Self-citation
Community pharmacist-administered injectable naltrexone for individuals who were formerly incarcerated: a review of Wisconsin legislation and regulations
Chladek, J. S., & Chui, M. A. (2025) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-025-00647-9 · Cited by 1
Therapeutic Communities and the Judicial System in the United States
Tuck, A. N., & Stossel, L. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-26273-0_8 · Cited by 1
Management of buprenorphine/naloxone therapy in substances abuse consumers in prison: efficacy and safety
Nava, F. A. (2018) · AboutOpen · doi:10.19156/abtpn.2018.0034
Medicolegal Considerations in the Management of Opioid Use Disorder With Buprenorphine in the Correctional Setting
Mitchell, M. N. (2021) · Journal of Correctional Health Care · doi:10.1089/jchc.19.06.0054
Overview and Summary: Substance Use Disorders and Related Concerns: Perspectives from Nurses
Fathi, J. T. (2020) · OJIN The Online Journal of Issues in Nursing · doi:10.3912/ojin.vol25no03manos
Développement de méthodes de classification basées sur l'analyse de concepts formels sous la plateforme WEKA.
Khalfi, B., Cherif, R., Meddouri, N., & Maddouri, M. (2010) · EGC eBooks
Determinants of health-related quality of life among individuals with opioid use disorder, recently released from incarceration
Cadet, T., Jalali, A., Jeng, P. J., Poole, S. A., WOODY, G. E., & Murphy, S. M. (2023) · Addiction Science & Clinical Practice · doi:10.1186/s13722-023-00375-0
Medications for Opioid Use Disorder (MOUDs): What Psychology Service Providers Should Know to Improve Correctional Care
Bassett, S. S., & Delaney, D. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-37480-7_11
Drug Court
Gallagher, J. R., & Nordberg, A. (2023) · doi:10.1093/oso/9780197694732.003.0026
Incarceration and Health: An Overview of Conditions and Solutions
Cullins, Z., Behne, M. F., Macmadu, A., Rich, J. D., & Brinkley‐Rubinstein, L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99967-0.00068-5

Authors: Gordon, M. S., Kinlock, T. W., Schwartz, R. P., Fitzgerald, T. T., O’Grady, K. E., & Vocci, F. J.
Affiliations: Stevenson University (US)
Friends Research Institute (US)
University of Maryland, Baltimore (US)
University of Maryland, College Park (US)
Corresponding author: Gordon, Michael S.
ORCID: Gordon, Michael S.
Schwartz, Robert P.
O’Grady, Kevin E.
Vocci, Frank J.
Venue: Drug and Alcohol Dependence
Publisher: Elsevier BV
Published: 2014-09
Volume: 142
Pages: 33-40
ISSN: 0376-8716 (ISSN-L)
DOI: 10.1016/j.drugalcdep.2014.05.011
PMC: PMC4129444
OpenAlex: W1979097541
Cited by: 112
References: 46
Citations by year: 2026: 3 · 2025: 6 · 2024: 12 · 2023: 12 · 2022: 10 · 2021: 12 · 2020: 9 · 2019: 13 · 2018: 8 · 2017: 5 · 2016: 11 · 2015: 9 · 2014: 1
FWCI: 8.59
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Drug and Alcohol Dependence (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute on Drug Abuse (R01DA021579)
Topics: Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Social Sciences › Sociology and Political Science › Criminal Justice and Corrections Analysis
Keywords: buprenorphine, heroin addiction, opioid use disorder, opioid-tolerant patients, community-based treatment, gender differences, treatment completion, drug diversion
MeSH terms: Adult, Buprenorphine, Combined Modality Therapy, Counseling, Female, Heroin Dependence, Humans, Male, Middle Aged, Narcotics, Prisoners, Prisons, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A randomized controlled trial of prison-initiated buprenorphine: Prison outcomes and community treatment entry

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks